EntreMed, Inc.: Survival Strategy in the Turbulent Biotech Industry
CASE STUDY. EntreMed’s new management team needed to revise the overall company strategy to survive.
David L. Entin
David Entin wrote this case study as Business Development Director at EntreMed Inc. He is now Director, Corporate Contracts, Licensing and Business Development at GlycoMimetics.
U.S. Biotech Industry Note
INDUSTRY NOTE. Strategy in a typical “biotech” company is determined by the capital markets rather than driven by customers.